Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
29 studies found for:    gdc-0973 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Condition: Solid or Brain Tumor With Evidence of RAS/RAF/MEK/ERK Activation
Intervention: Drug: Cobimetinib
2 Recruiting Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
Condition: Malignant Melanoma
Intervention: Drug: Cobimetinib + Vemurafenib combination treatment
3 Recruiting Single-agent Cobimetinib for Adults With Histiocytic Disorders
Condition: Histiocytic Disorders
Intervention: Drug: Cobimetinib
4 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
5 Recruiting A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
Condition: Melanoma
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
6 Recruiting Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC
Condition: Malignant Melanoma
Intervention: Drug: Vemurafenib + cobimetinib
7 Recruiting Vemurafenib Plus Cobimetinib in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vemurafenib plus cobimetinib;   Device: Positron Emission Tomography;   Procedure: Tissue sampling;   Procedure: Blood sampling
8 Recruiting A Study of Cobimetinib in Combination With Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Cobimetinib;   Drug: Paclitaxel;   Drug: Placebo;   Drug: Atezolizumab;   Drug: Nab-Paclitaxel
9 Recruiting ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Condition: Stage IIIB-C Melanoma
Intervention: Drug: Vemurafenib and Cobimetinib
10 Recruiting XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: XL888;   Drug: Vemurafenib;   Drug: Cobimetinib
11 Recruiting Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Condition: Melanoma, Malignant, of Soft Parts
Intervention: Drug: Vemurafenib and Cobimetinib
12 Recruiting Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Condition: Colorectal Cancer
Interventions: Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Cobimetinib
13 Recruiting Cobimetinib and Atezolizumab in Advanced Rare Tumors
Conditions: Malignant Neoplasms of Digestive Organs;   Melanoma and Other Malignant Neoplasms of Skin;   Appendiceal Adenocarcinoma;   Cutaneous Squamous Cell Carcinoma;   Small Bowel Adenocarcinoma
Interventions: Drug: Cobimetinib;   Drug: Atezolizumab
14 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
15 Recruiting Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Conditions: Metastatic Melanoma;   Melanoma;   BRAF-mutated Metastatic Melanoma;   V600EBRAF-mutated Metastatic Melanoma
Intervention: Drug: Vemurafenib + Cobimetinib, Decitabine
16 Recruiting Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: vemurafenib and cobimetinib
17 Recruiting A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma
Condition: Melanoma
Interventions: Drug: Atezolizumab;   Drug: Atezolizumab Placebo;   Drug: Cobimetinib;   Drug: Vemurafenib;   Drug: Vemurafenib Placebo
18 Recruiting A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Condition: Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
19 Recruiting Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib;   Drug: Atezolizumab
20 Not yet recruiting LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.